Treatment of MCI and Alzheimer's disease
View Patent ↗The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (AD)), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, lactam (e.g., a compound of formula (Ic) or (Ic-i), e.g., NFD-L1), thyroxine (T4), triiodothyronine (T3) and combinations thereof.
1. A method for treating Mild Cognitive Impairment (MCI) or Alzheimer's disease in a human subject, the method comprising
administering to a subject who is suffering from or susceptible to Mild Cognitive Impairment (MCI) or Alzheimer's disease a therapeutically effective amount of a lactam such that at least one symptom or feature associated with Mild Cognitive Impairment (MCI) or Alzheimer's disease is reduced in abundance, intensity, severity, or frequency, or has delayed onset; and wherein the lactam is NFD-L1,
2. The method of claim 1 , wherein the at least one symptom or feature is the production of amyloid beta protein.
3. The method of claim 1 , wherein the at least one symptom or feature is gamma-secretase activity, and wherein the gamma-secretase activity is reduced by inhibiting orphan G-coupled receptor 3 (GPCR-3) activity.
4. The method of claim 1 , wherein the at least one symptom or feature is phosphorylated tau protein in the brain.
5. The method of claim 1 , wherein the subject has an abnormal level of a biomarker as compared to a control, wherein the biomarker comprises:
at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and
at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, and/or serotransferrin protein.
6. The method of claim 5 , wherein the biomarker comprises prostaglandin-D2-synthase and transthyretin (PDS/TTR complex).
7. The method of claim 1 , wherein the subject has an abnormal level of a biomarker as compared to a control, wherein the biomarker comprises one or more of (i) beta amyloid 40 (Aβ40), (ii) beta amyloid 42 (Aβ42), (iii) the ratio of Aβ40 to Aβ42, and (iv) the ratio of phosphorylated tau to total tau.
8. The method of claim 1 , wherein the subject has a test score indicative of cognitive impairment.
9. The method of claim 8 , wherein the test score is an MMSE (Mini Mental Status Examination) score.
10. The method of claim 9 , wherein the MMSE score ranges from 21-26.
11. The method of claim 8 , wherein the test score is a clinical dementia rating (CDR) score.
12. The method of claim 11 , wherein the CDR score is 0.5 or 1.
13. The method of claim 1 , further comprising administering a therapeutic amount of nitroso-nifedipine to the subject.
14. The method of claim 1 , further comprising administering a mixture of nitrosonifedipine and oxidized nifedipine to the subject.
15. The method of claim 14 , wherein the mixture further comprises triiodothyronine (T3) and thyroxine (T4).
16. The method of claim 14 , wherein the mixture further comprises nifedipine.
17. The method of claim 16 , wherein the mixture comprises 55% nitroso-nifedipine, 11% oxidized nifedipine, and 34% nifedipine.
18. The method of claim 16 , wherein the mixture further comprises triiodothyronine (T3) and thyroxine (T4).
19. The method of claim 13 , wherein the therapeutically effective amount of nitrosonifedipine ranges from about 10 mg to about 2.5 g per dose.
20. The method of claim 1 , further comprising administering a mixture of triiodothyronine (T3) and thyroxine (T4) to the subject.
21. The method of claim 20 , wherein the mixture further comprises nifedipine.
22. The method of claim 1 , wherein the lactam does not function as a calcium channel blocker.